Patent intelligence · US
US 11298413
Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
Patent details — US 11298413
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 12, 2022
- Expiration
- Apr 7, 2042
- Applicant
- IO Biotech ApS
- Claims
- 5
- CPC classes
- A61K, A61K38/195, A61K39/0011, A61K39/001142
Quick answer
US 11298413 (Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof) is held by IO Biotech ApS. Status: granted. Granted Apr 12, 2022. Expires Apr 7, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IO Biotech ApS
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K38/195, A61K39/0011, A61K39/001142, A61K40/11, A61K40/4236
More from IO Biotech ApS
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
granted -
US 11981944
Immunogenic arginase peptides
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted
Frequently asked questions
What is US patent 11298413?
US 11298413 (Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof) is held by IO Biotech ApS. Status: granted. Granted Apr 12, 2022. Expires Apr 7, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11298413?
IO Biotech ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 11298413 expire?
Our index shows an expiration date of Apr 7, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.